CYP2C19 genotype is associated with symptomatic recurrence of GERD during maintenance therapy with low-dose lansoprazole.

BACKGROUND/AIMS: Maintenance therapy of gastroesophageal reflux disease (GERD) is usually performed with a low dose of a proton-pump inhibitor (PPI). Because PPIs are metabolized by CYP2C19 in the liver, we investigated whether a patient's CYP2C19 genotype was associated with symptomatic recurrence...

Full description

Bibliographic Details

Published in:	European Journal of Clinical Pharmacology Vol. 65; no. 7; pp. 693 - 699
Main Authors:	Furuta T, Sugimoto M, Kodaira C, Nishino M, Yamade M, Ikuma M, Shirai N, Watanabe H, Umemura K, Kimura M, Hishida A
Format:	research Journal Article
Published:	Springer Nature Jul2009
Online Access:	View this record in EBSCOhost